Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Maryland researchers win Komen grant to study breast treatment complications
As part $2m fund, Susan has granted $450,000 to a team led by Lisa Gallicchio at Mercy Medical Center to study why African American breast cancer patients may
As part $2m fund, Susan has granted $450,000 to a team led by Lisa Gallicchio at Mercy Medical Center to study why African American breast cancer patients may
In exchange for rights to jointly co-develop and co- market the products, Shionogi will pay a one time fee and share costs to Shire. Shire ADHD business senior
IDRI research lays emphasis on identifying new therapies to fight tuberculosis (TB), including multidrug-resistant TB (MDR-TB). The additional funding through Eli Lilly to support early stage TB drug
The miRNA reagents provide streamlined, high-fidelity target preparation methods yielding better data reproducibility in combination with the Affymetrix GeneChip Arrays. The reagents by Genisphere are said to be
Maintenance therapy using azathioprine or mycophenolate mofetil, helps consolidate remission and prevent relapse after the initial control of lupus nephritis. The 36-month, randomized, double-blind, double-dummy, phase 3 study
Alzheimer’s Society and Alzheimer Scotland are Tesco Charity of the Year 2011, which will provide the supermarket with leaflets and booklets as part of the program. Both the
Northera, a synthetic catecholamine increases the levels of norepinephrine, both centrally and peripherally. Previous Phase II trials demonstrated the efficacy of the drug in treating both intradialytic hypotension
Imprime PGG is an immunomodulatory drug, used as a treatment for cancer. The open label multicentre randomised trial involving 90 patients assessed the safety and efficacy of Imprime
The formulation is used to treat diseases associated with inappropriate insulin levels. Preclinical studies including Phase 1 and multicenter Phase 2 clinical trials have proven the efficacy of
Both the companies combined UHN’s human pluripotent stem cell biology expertise with VistaGen’s Human Clinical Trials in a Test TubeTM stem cell technology platform. The platform is believed